Biomarker & Intervention Discovery

GERD (Gastroesophageal Reflux Disease)

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Spontaneous remissionSymptom recurrence in 70-80% within 6 months of PPI discontinuation in erosive GERD; highly variable in non-erosive…
Best-intervention remissionWeight loss of >10% reduces symptoms in 65-81% of obese patients; laparoscopic anti-reflux surgery (Nissen…
Gap sizeLarge for lifestyle/surgical approaches vs standard chronic PPI use
Primary barrierframing/practice
Full remission profile →

Remission & chronicity

Spontaneous remission
Symptom recurrence in 70-80% within 6 months of PPI discontinuation in erosive GERD; highly variable in non-erosive disease; ~20% of GERD is nonerosive, where acid suppression is less effective
Best-intervention remission
Weight loss of >10% reduces symptoms in 65-81% of obese patients; laparoscopic anti-reflux surgery (Nissen fundoplication) achieves long-term symptom control in 85-92% and eliminates daily PPI need in majority; bariatric surgery in obese patients near-eliminates GERD
Gap size
Large for lifestyle/surgical approaches vs standard chronic PPI use
Primary barrier
framing/practice
AGA 2022 guidelines explicitly recommend PPI de-escalation or discontinuation in patients without erosive esophagitis or Barrett's — yet 84 million monthly Medicare PPI claims in 2019 suggest massive overprescription; most patients are never offered surgical or intensive lifestyle options
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ATP4A 226CHRM3 280CLDN1 0HRH2 218IL8 152PTGS2 299TJP1 4TRPV1 160
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NIFEDIPINE activates Mechanistic
EPIPREGNANOLONE SULPHATE activates Mechanistic
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE inhibits Mechanistic
PIOGLITAZONE HYDROCHLORIDE inhibits Mechanistic
HALOTHANE inhibits Mechanistic
NN-DIMETHYL-D-ERYTHROSPHINGOSINE activates Mechanistic
NA+ inhibits Mechanistic
PREGNENOLONE SULPHATE activates Mechanistic
(S)-LIQUIRITIGENIN inhibits Mechanistic
ILAPRAZOLE inhibits Mechanistic
CIM0216 activates Mechanistic
NARINGENIN inhibits Mechanistic
MAPROTILINE inhibits Mechanistic
TEGOPRAZAN inhibits Mechanistic
LA3+ inhibits Mechanistic
ISOSAKURANETIN inhibits Mechanistic
TROGLITAZONE inhibits Mechanistic
SPHINGOSINE activates Mechanistic
FEXUPRAZAN inhibits Mechanistic
PENTAFLUORO-TRITYL CLOTRIMAZOLE ANALOGUE 29A activates Mechanistic
GD3+ inhibits Mechanistic
ROSIGLITAZONE inhibits Mechanistic
DIHYDROSPHINGOSINE activates Mechanistic
PRIMIDONE inhibits Mechanistic
2-APB inhibits Mechanistic
OMEPRAZOLE MAGNESIUM inhibits Mechanistic
CHLOROFORM inhibits Mechanistic
MEFENAMIC ACID inhibits Mechanistic
PANTOPRAZOLE SODIUM inhibits Mechanistic
VONOPRAZAN FUMARATE inhibits Mechanistic
RABEPRAZOLE inhibits Mechanistic
OMEPRAZOLE inhibits Mechanistic 3800.0 nM (IC50)
ESOMEPRAZOLE SODIUM inhibits Mechanistic
LANSOPRAZOLE inhibits Mechanistic 398.11 nM (IC50)
ESOMEPRAZOLE STRONTIUM inhibits Mechanistic
DICLOFENAC SODIUM inhibits Mechanistic
ABEPRAZAN ? unclear Mechanistic
ESOMEPRAZOLE MAGNESIUM ? unclear Mechanistic
RABEPRAZOLE SODIUM ? unclear Mechanistic
DEXLANSOPRAZOLE ? unclear Mechanistic

Showing top 40 of 226 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
TARAFENACIN ? unclear Mechanistic
METHIXENE ? unclear Mechanistic
OXYBUTYNIN inhibits Mechanistic
CEVIMELINE HYDROCHLORIDE activates Mechanistic
ZAMIFENACIN ? unclear Mechanistic
IMIDAFENACIN inhibits Mechanistic
TIOTROPIUM ? unclear Mechanistic
BENZQUINAMIDE ? unclear Mechanistic
TOLTERODINE inhibits Mechanistic
OCTOTROPINE METHYLBROMIDE inhibits Mechanistic
SOLIFENACIN ? unclear Mechanistic
DOXEPIN HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL1084941 ? unclear Mechanistic
IPRATROPIUM CATION inhibits Mechanistic
PROMAZINE ? unclear Mechanistic
CLIDINIUM inhibits Mechanistic
BATEFENTEROL inhibits Mechanistic
BETHANECHOL CHLORIDE activates Mechanistic
OLANZAPINE ? unclear Mechanistic
OXYPHENCYCLIMINE ? unclear Mechanistic
TRIDIHEXETHYL ? unclear Mechanistic
ACETYLCHOLINE CHLORIDE activates Mechanistic
METHACHOLINE CHLORIDE activates Mechanistic
TRIDIHEXETHYL CHLORIDE inhibits Mechanistic
CYCLOPENTOLATE HYDROCHLORIDE inhibits Mechanistic
REVEFENACIN inhibits Mechanistic
PIPERTRAMINE ? unclear Mechanistic
FESOTERODINE inhibits Mechanistic
CCG-50014 ? unclear Mechanistic
ATROPINE SULFATE inhibits Mechanistic
PROMETHAZINE HYDROCHLORIDE ? unclear Mechanistic
ACLIDINIUM BROMIDE inhibits Mechanistic
TROPICAMIDE inhibits Mechanistic
DAROTROPIUM BROMIDE inhibits Mechanistic
ACECLIDINE ? unclear Mechanistic
SOLIFENACIN SUCCINATE inhibits Mechanistic
DEXAMETHASONE ? unclear Mechanistic
TIOTROPIUM BROMIDE inhibits Mechanistic
TROSPIUM inhibits Mechanistic
GLYCOPYRRONIUM inhibits Mechanistic

Showing top 40 of 280 agents ranked by evidence tier.

Pipeline results not yet available for this target. Run the pipeline to populate.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
NIZATIDINE inhibits Mechanistic
FAMOTIDINE inhibits Mechanistic
RANITIDINE BISMUTH CITRATE inhibits Mechanistic
BETAZOLE ? unclear Mechanistic
MS31 inhibits Mechanistic
RANITIDINE HYDROCHLORIDE inhibits Mechanistic
BETAZOLE HYDROCHLORIDE activates Mechanistic
EPINASTINE ? unclear Mechanistic
LAFUTIDINE inhibits Mechanistic
HISTAMINE ? unclear Mechanistic 463.0 nM (EC50)
TOLAZOLINE HYDROCHLORIDE activates Mechanistic
CIMETIDINE HYDROCHLORIDE inhibits Mechanistic
EBROTIDINE inhibits Mechanistic
DOXEPIN HYDROCHLORIDE ? unclear Mechanistic
METHANTHELINE BROMIDE inhibits Mechanistic
ASENAPINE ? unclear Mechanistic
CIMETIDINE inhibits Mechanistic
MS8535 inhibits Mechanistic
TOLAZOLINE ? unclear Mechanistic
METHANTHELINE ? unclear Mechanistic
RANITIDINE ? unclear Mechanistic
VUF-5297 activates Mechanistic 696.0 nM (EC50)
CHEMBL72424 inhibits Mechanistic 10000.0 nM (Ki)
CHEMBL70603 inhibits Mechanistic 10000.0 nM (Ki)
CHEMBL44220 inhibits Mechanistic 19952.62 nM (Ki)
CHEMBL72571 inhibits Mechanistic 3981.07 nM (Ki)
CHEMBL310087 inhibits Mechanistic 12589.25 nM (Ki)
CHEMBL70811 inhibits Mechanistic 1584.89 nM (Ki)
CHEMBL72372 inhibits Mechanistic 1584.89 nM (Ki)
CHEMBL418470 activates Mechanistic 93.0 nM (EC50)
CHEMBL308717 inhibits Mechanistic 5011.87 nM (Ki)
BURIMAMIDE inhibits Mechanistic 3981.07 nM (Ki)
VUF-5296 activates Mechanistic 2500.0 nM (EC50)
CHEMBL305929 inhibits Mechanistic 3162.28 nM (Ki)
CHEMBL104994 inhibits Mechanistic 22000.0 nM (Ki)
CHEMBL107293 inhibits Mechanistic 380.0 nM (Ki)
CHEMBL102840 inhibits Mechanistic 2300.0 nM (Ki)
CHEMBL104808 inhibits Mechanistic 500.0 nM (Ki)
CHEMBL105071 inhibits Mechanistic 730.0 nM (Ki)
CHEMBL101634 inhibits Mechanistic 6200.0 nM (Ki)

Showing top 40 of 218 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
VITAMIN A ? unclear Mechanistic
FENTANYL CITRATE ? unclear Mechanistic
ALPRAZOLAM ? unclear Mechanistic
FENRETINIDE ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
RECOMBINANT INTERLEUKIN-1 ? unclear Mechanistic
CIDOFOVIR ANHYDROUS ? unclear Mechanistic
DIPYRIDAMOLE ? unclear Mechanistic
TROGLITAZONE ? unclear Mechanistic
LANSOPRAZOLE ? unclear Mechanistic
IONOMYCIN ? unclear Mechanistic
E319 ? unclear Mechanistic
CEFTRIAXONE ? unclear Mechanistic
CHLORDANE ? unclear Mechanistic
FOSCARNET ? unclear Mechanistic
ADAKITUG inhibits Mechanistic
DANAZOL ? unclear Mechanistic
D-ALPHA-TOCOPHEROL ACETATE ? unclear Mechanistic
DICYCLOHEXYLCARBODIIMIDE ? unclear Mechanistic
RO 31-8220 ? unclear Mechanistic
BEVACIZUMAB ? unclear Mechanistic
BROXURIDINE ? unclear Mechanistic
TRETINOIN ? unclear Mechanistic
ALL-TRANS-RETINAL ? unclear Mechanistic
METHIMAZOLE ? unclear Mechanistic
DEOXYSPERGUALIN ? unclear Mechanistic
PAZOPANIB ? unclear Mechanistic
OMEPRAZOLE ? unclear Mechanistic
ALPHA-TOCOPHEROL ACETATE ? unclear Mechanistic
MEDROXYPROGESTERONE ACETATE ? unclear Mechanistic
ASPIRIN ? unclear Mechanistic
TETRADECANOYLPHORBOL ACETATE ? unclear Mechanistic
PENTOXIFYLLINE ? unclear Mechanistic
PYROGALLOL ? unclear Mechanistic
KLEBSIELLA PNEUMONIAE GLYCOPROTEIN ? unclear Mechanistic
ABX-IL8 inhibits Mechanistic
FLUOROURACIL ? unclear Mechanistic
BIOFLAVONOID ? unclear Mechanistic
LEFLUNOMIDE ? unclear Mechanistic
QUESTIOMYCIN B ? unclear Mechanistic

Showing top 40 of 152 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARPROFEN inhibits Mechanistic 102.0 nM (IC50)
INDOMETHACIN SODIUM inhibits Mechanistic
DARBUFELONE ? unclear Mechanistic
MEFENAMIC ACID inhibits Mechanistic
MECLOFENAMATE SODIUM inhibits Mechanistic
DICLOFENAC SODIUM inhibits Mechanistic
CAPECITABINE ? unclear Mechanistic
PIRPROFEN inhibits Mechanistic
ESFLURBIPROFEN inhibits Mechanistic
SULFASALAZINE inhibits Mechanistic
BROMFENAC ? unclear Mechanistic
IBUPROFEN, SODIUM SALT inhibits Mechanistic
ALOXIPRIN inhibits Mechanistic
TENOXICAM ? unclear Mechanistic
FLURBIPROFEN inhibits Mechanistic
SALICYLIC ACID ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
DEXKETOPROFEN inhibits Mechanistic
ETORICOXIB inhibits Mechanistic
LUMIRACOXIB inhibits Mechanistic
SUPROFEN inhibits Mechanistic
NS-398 ? unclear Mechanistic
NABUMETONE inhibits Mechanistic
URSOLIC ACID ? unclear Mechanistic
IBUPROFEN LYSINE inhibits Mechanistic
ACECLOFENAC inhibits Mechanistic
IBUFENAC inhibits Mechanistic
BALSALAZIDE ? unclear Mechanistic
DIFLUNISAL inhibits Mechanistic
BALSALAZIDE DISODIUM inhibits Mechanistic
VACCINE ? unclear Mechanistic
KETOROLAC TROMETHAMINE inhibits Mechanistic
BENZYDAMINE HYDROCHLORIDE inhibits Mechanistic
TIAPROFENIC ACID ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic
NAPROXCINOD inhibits Mechanistic
IGURATIMOD inhibits Mechanistic
ETODOLAC inhibits Mechanistic
DICLOFENAC ETALHYALURONATE SODIUM inhibits Mechanistic
ROFECOXIB inhibits Mechanistic 530.0 nM (IC50)

Showing top 40 of 299 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
DEXAMETHASONE ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
DEHYDRATED ALCOHOL ? unclear Mechanistic
GENISTEIN ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
STREPTOZOCIN ? unclear Mechanistic
BENZYL ISOTHIOCYANATE ? unclear Mechanistic
ACETAMINOPHEN activates Mechanistic
POLYGODIAL ? unclear Mechanistic
PROPOFOL ? unclear Mechanistic
SAF312 inhibits Mechanistic
GRC-15300 ? unclear Mechanistic
AZD1386 inhibits Mechanistic
TIVANISIRAN inhibits Mechanistic
MAVATREP inhibits Mechanistic
MR-1817 inhibits Mechanistic
FERRUGINENE B ? unclear Mechanistic
CAPSAICIN activates Mechanistic 19.95 nM (EC50)
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic
VOACANGINE ? unclear Mechanistic
RESINIFERATOXIN activates Mechanistic 23.1 nM (Ki)
DWP05195 inhibits Mechanistic
XEN-D0501 inhibits Mechanistic
PAC-14028 inhibits Mechanistic
SB-705498 inhibits Mechanistic
MASOPROCOL ? unclear Mechanistic
ALLYL ISOTHIOCYANATE ? unclear Mechanistic
NGD-8243 inhibits Mechanistic
GRC-6211 inhibits Mechanistic
RESERPINE ? unclear Mechanistic
NABIXIMOLS ? unclear Mechanistic
A425619 ? unclear Mechanistic
PHE377 inhibits Mechanistic
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic
WORTMANNIN ? unclear Mechanistic
JTS-653 inhibits Mechanistic
LEVODOPA ? unclear Mechanistic
AMG517 inhibits Mechanistic
CAPSAZEPINE ? unclear Mechanistic 120.0 nM (Ki)
ZUCAPSAICIN activates Mechanistic
INDOMETHACIN ? unclear Mechanistic
CHEMBL:CHEMBL191534 ? unclear Mechanistic
ABT-102 inhibits Mechanistic
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic

Showing top 40 of 160 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-06.

No recent clinical trials found on ClinicalTrials.gov for this condition.


Agents Found By Disease-Level Search

Searched directly from “GERD (Gastroesophageal Reflux Disease)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

60 agents shown (approved or with trial evidence) — 54 not found by the gene-target search above.

Esomeprazole

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT04329000 NCT00317044 NCT00317044

pantoprazole

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00362609 NCT00307944 NCT01887743

Lansoprazole

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01990339 NCT01135368

Vonoprazan

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05366738 NCT05366738

Dexlansoprazole

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02616302 NCT00627016

Esomeprazole 40 mgNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT04568772 NCT04329000

AZD3355NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00757419

EG Scan II (transnasal endoscopy)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02066233

Standard EndoscopyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02066233

Lap Nissen fundoplication with division of short gastric vesselsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00852098

Laparoscopic Nissen fundoplication without division of short gastric vesselsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00852098

Standard dose (once daily) PPI plus low-dose antidepressantNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

Double dose PPI plus evening placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

Rabeprazole , placebo, placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

gastroenteroanastomosis simultaneous to vertical sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07537244

vertical sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07537244

NortriptylineNOT in gene-target list

Phase 2/3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01065649

Placebo armNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01065649

Thickened infant formulaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02710955

Medtronic Intrepid™ TMVR TF SystemNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05496998

Dexrabeprazole 10 mg Enteric-Coated TabletsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02689999

Omeprazole

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00256737

High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06151067

AciphexNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00204698

DIMAC02NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02789800

Atovaquone / Proguanil 250/100 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

Tegoprazan 50 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

Vonoprazan 20 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

YYD601 40mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

Nexium 40mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

PlacebosNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

Laparoscopic total left-sided surgical approachNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07252115

Laparoscopic traditional bilateral approachNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07252115

laparoscopic surgeryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01587859

Intravenous FamotidineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06241183

Oral Maalox/ MylantaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06241183

patients with GERD after LSGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05416645

Esophageal studiesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05180253

Endoscopic gastroplicationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00235677

Alginate-antacid groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03516188

Non antacid alginate groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03516188

Swallowable Sponge Cell Sampling DeviceNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02890979

Laparoscopic fundoplication (surgery)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251927

CKD-381NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03211143

NexiumNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03211143

Tracheal LavageNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00865995

24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04454112

sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04994665

sleeve gastrectomy with omentopexyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04994665

One Anastomosis Gastric Bypass (OAGB)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04422405

ZegeridNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01710995

LosecNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01710995

AG1321001(drug)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00380315

IW-3718NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02030925

Matching PlaceboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02030925

commercially available lansoprazoleNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03015610

matched placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03015610

SAPIEN Transcatheter Valve ImplantationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00676689

Cognitive Behavioral Therapy (CBT)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06939465

Lifestyle management (sham control)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06939465

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.